You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • SAT0307 Lesinurad Monotherapy in Gout Patients Intolerant to Xanthine Oxidase Inhibitors (Light): A Randomized, Double-Blind, Placebo-Controlled, 6-Month Phase III Clinical Trial

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
SAT0307 Lesinurad Monotherapy in Gout Patients Intolerant to Xanthine Oxidase Inhibitors (Light): A Randomized, Double-Blind, Placebo-Controlled, 6-Month Phase III Clinical Trial

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20151400
Jul 2015801
Aug 20152903
Sep 20152314
Oct 20151201
Nov 20152009
Dec 20153107
Jan 20167318
Feb 201678017
Mar 201681113
Apr 20166905
May 20162305
Jun 20162814
Jul 20163200
Aug 20164905
Sep 20163303
Oct 20165203
Nov 201612301
Dec 20164301
Jan 20173804
Feb 20176603
Mar 20174507
Apr 20174104
May 20173804
Jun 20174905
Jul 20172802
Aug 20178005
Sep 20178108
Oct 20178301
Nov 20176001
Dec 20174800
Jan 20187001
Feb 20186002
Mar 20188200
Apr 20189804
May 20186801
Jun 20185401
Jul 20186400
Aug 20183401
Sep 20182000
Oct 20183400
Nov 20185202
Dec 20182602
Jan 20192104
Feb 20191500
Mar 2019900
Apr 2019500
May 20192200
Jun 20191100
Jul 20192301
Aug 2019800
Sep 20191002
Oct 2019700
Nov 20191800
Dec 20191600
Jan 2020800
Feb 2020800
Mar 20202603
Apr 2020400
May 20201400
Jun 20201000
Jul 20201300
Aug 2020600
Sep 20202300
Oct 20202301
Nov 20201600
Dec 2020900
Jan 2021300
Feb 20211302
Mar 2021500
Apr 2021900
May 2021100
Jun 2021200
Sep 2021900
Oct 20212501
Nov 2021600
Dec 20212900
Jan 2022702
Feb 2022300
Mar 2022501
Apr 2022500
May 2022800
Jun 2022800
Jul 20223200
Aug 2022900
Sep 20221900
Oct 20222200
Nov 20221800
Dec 20221100
Jan 2023500
Feb 20231100
Mar 2023600
Apr 20233601
May 2023600
Jun 2023500
Jul 2023600
Aug 2023600
Sep 2023600
Oct 2023300
Nov 20231400
Dec 20234600
Jan 2024800
Feb 2024800
Mar 2024900
Total28894166